SPOTLIGHT: GSK's Arixtra losing to Rivaroxaban


A research report concludes that GlaxoSmithKline's anti-clotting drug Arixtra is losing ground to Rivaroxaban, made and marketed by Bayer Schering/Johnson & Johnson. Released by Decision Resources, the report cites Arixtra's need for close monitoring and its potential for serious side effects such as hemorrhage. Article

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.